Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 15, 2025
- Pharmaceuticals
- R&D
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Two Phase III Trials for Type 2 Diabetes)
TOKYO, October 15, 2025 -- Chugai Pharmaceutical Co., Ltd. (hereafter “Chugai”, TOKYO: 4519) announced that Eli Lilly and Company (hereafter “Eli Lilly”, NYSE: LLY) issued a news release on October 15, 2025 (local time) regarding topline Phase 3 results from ACHIEVE-2 and ACHIEVE-5 trials of orforglipron. Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights.
For the full text of Eli Lilly's news release, please refer to the Latest News via the following link:
Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
https://investor.lilly.com/
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp